Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved by FDA for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma, respectively. From then, increasing number of researchers have been dedicated to CAR-T cell therapy research.
What is CAR-T cell therapy? It is a kind of immunotherapy mainly about isolating the patient's T cells and genetically engineering the cells to express chimeric antigen receptors (CARs), which can recognize a specific tumor associated antigen, such as CD19, BCMA and CD20. After infusing the engineered CAR-T cells into the body, the tumors cells are targeted efficiently.
Before infusing CAR-T cells into patients, CAR+% assay through flow cytometry is inevitable. The most commom method for CAR+% detection is using target protein as detection reagents. Sino Biological has successfully developed over 6000 recombinant proteins, covering most of the investigational CAR-T cell therapy targets. We have developed biotinylated proteins and fluorescent labeled proteins to simplify your research procedures. The proteins with high purity and high binding activity, have also been validated in high-class citations. Therefore, CAR-T cell therapy target proteins in Sino Biological Inc. are the first choice for your scientific research.
Official name | Alias | Diseases |
CA9 | CAIX | metastatic renal cell carcinoma |
CD274 | PD-L1 | glioblastoma |
CD70 | b-cell malignancies, pancreatic cancer, renal cell cancer, breast cancer, melanoma, ovarian cancer | |
![]() |
||
CEACAM5 | CEA | a variety of solid tumors(lung cancer,colorectal cancer,gastric cancer, breast cancer and pancreatic cancer ) |
EGFR | colorectal cancer | |
EGFRvIII | glioblastoma | |
EPCAM | CD326 | hepatoma, gastric cancer |
EPHA2 | malignant glioma | |
ERBB2 | HER2 | a variety of solid tumors (breast cancer,ovarian cancer,lung cancer,gastric cancer, glioma, pancreatic cancer) |
FAP | malignant pleural mesothelioma | |
FOLH1 | PSMA | prostate cancer |
FOLR1 | FRα | ovarian cancer |
GPC3 | Glypican-3 | hepatocellular carcinoma, squamous cell lung cancer |
IL13RA2 | glioma | |
KDR | VEGFR2 | metastatic carcinoma, metastatic melanoma, renal cancer |
L1CAM | CD171 | ovarian cancer, neuroblastoma |
MET | c-MET | breast cancer |
MSLN | Mesothelin | mesothelioma, pancreatic cancer, ovarian cancer |
Muc1 | CA15-3 | hepatocellular carcinoma, non-small cell lung cancer, pancreatic cancer, breast cancer |
PROM1 | CD133 | liver cancer, pancreatic cancer, brain tumor, breast cancer, ovarian tumor, colorectal cancer, acute myeloid and lymphoid leukemias |
ROR1 | non-small cell lung cancer | |
ULBP1 | NKG2D ligand 1 | ovarian tumor, a variety of hematological malignancies |
ULBP2 | NKG2D ligand 2 | ovarian tumor, a variety of hematological malignancies |
Official name | Alias | Diseases |
CD19 | leukemia, lymphoma, multiple myeloma | |
CD22 | Siglec-2 | b-cell lymphoma |
CD33 | Siglec-3 | myeloid malignancies |
![]() |
||
CD38 | acute myeloma leukemia, multiple myeloma | |
CD5 | Leu-1 | t cell acute lymphoblastic lymphoma |
CD7 | acute myeloid and lymphoid leukemia | |
IL1RAP | IL1R3 | chronic myeloid leukemia |
IL3RA | CD123 | myeloid malignancies |
MS4A1 | CD20 | leukemia, lymphoma, multiple myeloma |
NCAM1 | CD56 | acute myeloma leukemia |
PROM1 | CD133 | liver cancer, pancreatic cancer, brain tumor, breast cancer, ovarian tumor, colorectal cancer, acute myeloid and lymphoid leukemias |
ROR1 | non-small cell lung cancer, breast cancer, leukemia | |
SDC1 | CD138 | multiple myeloma |
TNFRSF17 | BCMA | multiple myeloma |
TNFRSF8 | CD30 | lymphoma |
ULBP1 | NKG2D ligand 1 | a variety of hematological malignancies, ovarian tumor |
ULBP2 | NKG2D ligand 2 | a variety of hematological malignancies, ovarian tumor |
Title: Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers
Authors: Zhang C, et al.
Journal: Molecular Therapy
Fig. 1 CAR expression were detected in CAR-T cells by FCM method using CEA protein (Cat. No. 11077-H08H). The median CAR+% is 33.7% and the range is 14.7%–43.2%.
PBMCs were activated by immobilized CD3 and CD28 antibodies. On day 2, T cells were infected with lentiviral vector in six-well plates with polybrene. After viral transduction, T cells were expanded by IL-2 for approximately 12–14 days to obtain enough cell dose. Quality control of cell products was performed by FCM. For the cell products, the CAR+ %, proportion of T cells (CD3+), NK cells (CD16+CD56+), NKT cells (CD3+CD16+CD56+), CD4/8 ratio, T memory cells, and checkpoint inhibitors (TIM-3, PD-1, LAG-3) on the T cell surface were measured on the day before CAR-T infusion. To ensure transfection, CAR+ % detection 4–5 days after viral transfection were also applied.
Title: Chimeric antigen receptor
Authors: Shiku H, et al.
Journal: US 9,175,308 B2
Fig. 2 CAR-positive rate was detected using Recombinant Human EGFR (from Sino Biological Inc.). The CAR-positive rate is relative to copy numbers of the retrovirus.
A human PBMC which had been collected after obtaining informed consent was infected two times with an undiluted solution or a 2-fold, 4-fold or 8-fold dilution of each virus solution to prepare a PBMC expressing anti-EGFR-CAR. Five days after the second virus infection, Recombinant Human EGFR in which the C-terminal end was His-tag-modified was added to the infected cells, and then a biotin-labeled anti-His-tag antibody was added. There after, the cells were stained with streptavidin-PE and a FITC labeled anti-Human CD8 antibody. Using a flow cytometer, the stained cells were subjected to measurement of a rate of PE-positive cells in FITC-positive cells, that is, a rate of cells positive for CAR that binds to EGFR in CD8-positive cells. Further, the infected cells were recovered 5 days after the second virus infection, and subjected to measurement of the number of copies of the virus incorporated into the genome.
Fig. 3 The purity of human BCMA protein (ECD, Fc Tag) (Cat. No. 10620-H38H) is >95% as determined by SDS-PAGE.
Fig. 4 The purity of human Mesothelin protein (Fc Tag) (Cat. No. 13128-H02H) is >99% as determined by SDS-PAGE.
Fig. 5 Flow cytometric analysis of FITC-CD19 protein (Cat. No. 11880-H08H-F) on CD19-CAR transfected 293 cells.
Fig. 6 The biotinylayed human Glypican-3 protein (Cat. No. 10777-H08H-B) and unconjugated human Glypican-3 protein (Cat. No. 10777-H08H) binds CD20 antibody drugs in a functional ELISA.
• Sino Biological provide ready-to-use biotinylated proteins for most of the CAR-T cell therapy targets, all of which go through strict QC standard and show high activity. To learn more about biotinylated proteins.
• Fluorescent labeled proteins are also under quick research and will be in the sale soon!
If you can not find the protein you need, we also offer custom service for protein production. With five protein expression systems and years of experience, we are professional in recombinant protein production. To find more……